Evidence map›Paper›PMID 35301634›Full record

ArticleInflammation2022

Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy of Novel Drugs.

Kayla F Goliwas, Mahendra P Kashyap, Jasim Khan, Rajesh Sinha, Zhiping Weng, Allen S W Oak, Lin Jin, Venkatram Atigadda, Madison B Lee, Craig A Elmets and 4 more

Abstract read
In one paragraph

Article in Inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kayla F GoliwasDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Mahendra P KashyapUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Jasim KhanUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Rajesh SinhaUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Zhiping WengUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Allen S W OakDepartment of Dermatology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Lin JinUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Venkatram AtigaddaUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Madison B LeeUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Craig A ElmetsUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
M Shahid MukhtarDepartment of Biology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Chander RamanUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Jessy S DeshaneDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. jessydeshane@uabmc.edu.ORCID http://orcid.org/0000-0002-6761-5662
Mohammad AtharUAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. mohammadathar@uabmc.edu.

Funding

RXR Rexinoids for Cancer ChemopreventionP01CA210946 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2017 to 2021
$7.3M
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed miceR01ES026219 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2016 to 2020
$1.7M
NCI NIH HHS 5P01CA210946NCI NIH HHS P01 CA210946NIEHS NIH HHS R01 ES026219NIH HHS RO1 ES026219
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is a complex and debilitating inflammatory skin disease for which no effective treatment is available currently. This is partly because of the lack of adequate human or animal models for defining the pathobiology of the disease. Here, we describe the development of air-liquid (A-L) interface, liquid-submersion (L-S), and bioreactor (Bio) ex vivo skin culture models. All three ex vivo platforms were effective for culturing skin samples for up to 14 days. Tissue architecture and integrity remained intact for at least 3 days for healthy skin and 14 days for HS skin. Up to day 3, no significant differences were observed in % early apoptotic cells among all three platforms. However, late apoptotic/necrotic cell death was increased in HS skin at day 3 in A-L and Bio culture. These cultures efficiently support the growth of various cells populations, including keratinocytes and immune cells. Profiling inflammatory gene signatures in HS skin from these ex vivo cultures showed dynamic changes in expression at day 3 and day 14. All three culture platforms were necessary to represent the inflammatory gene status of HS skin at day 0, suggesting that not all gene clusters were identically altered in each culture method. Similarly, cytokine/chemokine profiling of the supernatants from vehicle- and drug-treated ex vivo HS cultures again showed a better prediction of drug efficacy against HS. Overall, development of these three culture systems collectively provides a powerful tool to uncover the pathobiology of HS progression and screen various drugs against HS.

Indexed as

Hidradenitis SuppurativaAnimalsCytokinesKeratinocytesSkinTreatment OutcomeCytokinesCytokines/chemokinesDrug screening.Ex vivo modelsHidradenitis suppurativa

Identifiers

PMID35301634
PMCPMC9940461

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.